Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/09/2777188/0/en/Ikena-Oncology-Shares-Initial-Positive-and-Differentiated-Dose-Escalation-Data-from-IK-930-Phase-I-Trial-and-Reports-Third-Quarter-2023-Financial-Results.html

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions

Read more at globenewswire.com

Related news for (IKNA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.